SlideShare une entreprise Scribd logo
1  sur  27
Télécharger pour lire hors ligne
INSULIN AND
ANTIDIABETIC DRUGS
BY
DR VISHAL KR KANDHWAY
JNMC, SAWANGI (MEGHE), WARDHA
PANCREATIC AXIS
INSULIN
-β cells secrete due to high
blood glucose levels
-Glucose uptake into tissues
increases
GLUCAGON
-α cells secrete when blood
glucose is low
-Glucose is released from tissues
back into blood
GLUCOSE HOMEOSTASIS
Body
Cells take up
more glucose
Liver takes
up glucose
and stores it as
glycogen
Blood glucose level
declines to a set point;
stimulus for insulin
release diminishes
Homeostasis: Normal blood glucose level
(about 90 mg/100 mL)
STIMULUS:
Rising blood glucose
level (e.g., after eating
a carbohydrate-rich
meal)
Beta cells
of pancreas stimulated
to release insulin into
the blood
High blood
glucose level
Blood glucose level
rises to set point;
stimulus for glucagon
release diminishes
Liver
breaks down
glycogen and
releases glucose
to the blood
Glucagon
Alpha
cells of
pancreas stimulated
to release glucagon
into the blood
STIMULUS:
Declining blood
glucose level
(e.g., after
skipping a meal)
Insulin
NORMAL GLUCOSE CONTROL
 Post-absorptive period - normal individual-low basal levels of
circulating insulin maintained through constant β cell secretion-
suppression of lipolysis, proteolysis and glycogenolysis.
 After ingesting a meal-burst of insulin secretion in response to
elevated glucose and amino acid levels.
 When glucose levels return to basal levels- insulin secretion
returns to its basal level.
DIABETES MELLITUS
-Definition- Diabetes is a heterogeneous group of syndromes
characterized by the elevation of glucose levels due to a relative
or absolute deficiency of insulin.
-It is characterized by-
1. High level of glucose in urine and fasting blood
2. Polyuria
3. Polydypsia
4. Fatigue
5. Constant hunger
TYPES
 Type 1 DM:
- “Childhood” diabetes (sudden onset, before age 15)
- Lack of functional pancreatic β-cells (T cell-mediated autoimmune response
destroys beta cells)
- Lack of functional β-cells prevents mitigation of elevated glucose levels and
associated insulin responses.
- Controlled by insulin injections.
 Type 2 DM:
- “Adult” diabetes (after age 40, obese individuals)
- Insulin levels are normal or elevated but there is either a decrease in number of
insulin receptors or the cells cannot take it up.
- Actual insulin levels may be normal or supra-normal but it is ineffective
(insulin resistance).
- Controlled by dietary changes and regular exercise.
TREATMENT
 Type I DM :
- Depend on exogenous insulin to prevent hyperglycemia and avoid
ketoacidosis.
- The goal of therapy is to mimic both the basal and reactive secretion of insulin
in response to glucose levels avoiding both hyper- and hypo-glycemic
episodes.
 Type II DM:
- The goal of treatment is to maintain glucose concentrations within normal
limits to prevent long term complications.
- Weight reduction, exercise and dietary modification decrease insulin resistance
- essential steps in the treatment regimen.
- Addition of hypoglycemic agents is often required, often insulin therapy is
also required.
INSULIN
 Insulin- peptide hormone
synthesized in the beta cells of
islets of Langerhans in the
Pancreas.
 Produced as a polypeptide- Pro
insulin (precursor)
 Proinsulin converted to insulin
and C-peptide and stored in the
secretory granules.
 Stimulation leads to release of
secretory granules.
MECHANISM OF ACTION
 Secretion elicited by elevated glucose levels
 Increased glucose levels in β-cells results in increased ATP levels, this results
in a block of K+ channels causing membrane depolarization which opens Ca2+
channels.
 The influx of Ca2+ results in a pulsatile secretion of insulin.
 Many insulin stimulated cascades are activated mainly translocation of GLUT
4 glucose transporters to plasma membranes causing-
1. Glucose diffusion into cells
2. Activates glycogen synthetase and thus glucose stored as glycogen
3. Stimulate uptake of amino acids, potassium and magnesium
4. Stimulate protein synthesis and inhibit proteolysis
 1 unit of can account for 30 grams of carbohydrate
 1 unit can lower 50 mg/dL blood glucose
ACTION OF INSULIN ON VARIOUS
TISSUES
LIVER MUSCLE ADIPOSE
↓ GLUCOSE
PRODUCTION
↑ GLUCOSE
TRANSPORT
↑ GLUCOSE
TRANSPORT
↑ GLYCOLYSIS ↑ GLYCOLYSIS ↑ LIPOGENESIS&
LIPOPROTEIN
LIPASE ACTIVITY
↑ TG SYNTHESIS ↑ GLYCOGEN
DEPOSITION
↓ INTRACELLULAR
LIPOLYSIS
↑ PROTEIN
SYNTHESIS
↑ PROTEIN
SYNTHESIS
The Synthesis and Release of Insulin is modulated by:
1. Glucose (most important) and ketone bodies stimulate release.
2. Glucagon and somatostation inhibit release
3. α-Adrenergic stimulation inhibits release (most important).
4. β-Adrenergic stimulation promotes release.
5. Elevated intracellular Ca2+ promotes release.
PHARMACOKINETICS
 Elimination t ½ of IV insulin- 5 to 10 minutes
 Metabolized by kidneys and liver
 Insulin tightly bound to tissue receptors- so even though rapid clearance,
pharmacologic effects remain till 30-60 minutes.
 Insulin secreted into portal venous system at rate of 1 unit/hour
 Daily secretion of insulin is 40 units.
 Insulin response to glucose is greater for oral ingestion than for iv infusion.
PREPARATIONS
HOURS AFTER SUBCUTANEOUS ADMINISTRATION
INSULIN
PREPARATION ONSET PEAK DURATION
RAPID ACTING
REGULAR CRYSTALLINE
ZINC
0.5-1.0 2-3 6-8
VERY RAPID ACTING
LISPRO
ASPART
0.25-0.5 0.5-1.5 4-6
INTERMEDIATE ACTING
LENTE(NPH)
1 4-8 10-14
LONG ACTING
ULTRALENTE
GLARGINE
1
1.5
10-14
none
18-24
30
THE GOAL OF INSULIN THERAPY
PREPARATIONS
 Regular Insulin
- Fast acting (rapid acting)
- Only type which can be given IV as well as SC
- Six molecules linked with a zinc molecule to form hexamer
- For abrupt onset hyperglycemia or ketoacidosis
- Single iv injection 1-5Units/ continuous infusion of 0.5-2 units/hour
 VERY RAPID ACTING- LISPRO/ INSULIN ASPART/ GLULISINE-
(ultrashort acting)
- More rapid than regular insulin and shorter duration
- Less Associated hypoglycemia but recurrent hyperglycemia before next meal due
to shorter duration of action.
- Given just 15 minutes prior to meals
- Provides a postprandial plasma insulin concentration like normal insulin.
 INTERMEDIATE ACTING- LENTE (NPH)
- Absorption delayed due to conjugation with protamine(0.005mg/unit)
 LONG ACTING- ULTRALENTE, GLARGINE
- Given as single bedtime injection
- Lesser nocturnal hypoglycemia
Insulin and antidiabetics
ADVERSE EFFECTS OF INSULIN
 Hypoglycemia
 Allergic reactions
 Lipodystrophy
 Insulin resistance
 Hypokalemia
 Weight gain
ORAL HYPOGLYCEMICS
 These agents are useful in the treatment of Type 2 DM who do not respond
adequately to non-medical interventions (diet, exercise and weight loss).
 Newly diagnosed Type 2 DM (less than 5 years) often respond well to oral
agents
 Patients with long standing disease (often diagnosed late) require a
combination of agents with or without insulin.
 The progressive decline in β-cell function often necessitates the addition of
insulin at some time in Type II DM. Oral agents are never indicated for Type I
DM.
SULFONYLUREAS
 Promote the release of insulin from β-cells (secretogogues)
 Mechanism of action:
 These agents require functioning β-cells, they stimulate release by blocking
ATP-sensitive K+ channels resulting in depolarization with Ca2+ influx
which promotes insulin secretion.
 They also reduce glucagon secretion and increase the binding of insulin to
target tissues.
 They may also increase the number of insulin receptors
-Adverse Effects: Weight gain, Hyperinsulinemia and Hypoglycemia. Hepatic or
renal insufficiency causes accumulation of these agents promoting the risk of
hypoglycemia.
 Tolbutamide is asociated with a 2.5 times rise in cardiovascular mortality.
Onset and Duration
 Short acting: Tolbutamide
 Intermediate acting: Glipizide ,Glyburide
 Long acting: Chloropropamide, Glimepride
MEGLITINIDES
 Agents -Repaglinide and Nateglinide act as Secretogogues.
 Prompt peak effect (1 hour) and shorter duration of action (about 4 hours)
 Taken 15-30 mins before meals
 Decreases risk of prolonged hypoglycemia due to short duration of action.
 When used in combination with other oral agents they produce better control
than any monotherapy.
BIGUANIDES
 METFORMIN
- Classified as an insulin sensitizer- increases glucose uptake and utilization by target
tissues
- Mechanism of action : Reduces plasma glucose levels by inhibiting hepatic
gluconeogenesis.
- It also reduces hyperlipidemia (↓LDL and VLDL cholesterol and ↑ HDL). Lipid
lowering requires 4-6 weeks of treatment.
- Metformin also decreases appetite.
- It is the only oral hypoglycemic shown to reduce cardiovascular mortality.
- Adverse effects: Hypoglycemia occurs only when combined with other agents.
Rarely severe lactic acidosis is associated with metformin use particularly in
diabetics with CHF. Drug interactions with cimetidine, furosemide, nifedipine and
others have been identified.
THIAZOLIDINEDIONES (GLITAZONES)
 PIOGLITAZONE and ROSIGLITAZONE
 These agents are insulin sensitizers
 They do not promote insulin secretion from β-cells but insulin is necessary for
them to be effective
 Act principally at adipose tissue and skeletal muscles to decrease insulin
resistance
 Clinical effect takes 4-12 weeks to be evident
 SIDE EFFECTS- Weight gain, can induce hepatic dysfunction
ΑLPHA-GLUCOSIDASE INHIBITORS
 Acarbose and miglitol are two agents of this class used for type 2 diabetes
Mechanism of action: These agents are oligosaccharide derivatives taken at the
beginning of a meal ; delay carbohydrate digestion by competitively inhibiting
α-glucosidase, a membrane bound enzyme of the intestinal brush border.
Adverse Effects: Flatulence, diarrhea, cramping.
Metformin bioavailability is severely decreased when used concomitantly.
These agents should not be used in diabetics with intestinal pathology.
Insulin and antidiabetics
REFERENCES
 Stoelting’s pharmacology and physiology in anaesthetic
practice

Contenu connexe

Tendances (20)

Thyroid & antithyroid drug
Thyroid & antithyroid drugThyroid & antithyroid drug
Thyroid & antithyroid drug
 
Insulin preparations
Insulin preparationsInsulin preparations
Insulin preparations
 
Pharmacology - Parkinsonism
Pharmacology - ParkinsonismPharmacology - Parkinsonism
Pharmacology - Parkinsonism
 
Anti-Rheumatic drugs
Anti-Rheumatic drugsAnti-Rheumatic drugs
Anti-Rheumatic drugs
 
Anti diabetic drugs
Anti diabetic drugsAnti diabetic drugs
Anti diabetic drugs
 
Diuretics
DiureticsDiuretics
Diuretics
 
Sulfonylureas
SulfonylureasSulfonylureas
Sulfonylureas
 
Oral Hypoglycemic Agents
Oral Hypoglycemic AgentsOral Hypoglycemic Agents
Oral Hypoglycemic Agents
 
Drugs for constipation
Drugs for constipationDrugs for constipation
Drugs for constipation
 
Metformin A Pharmacological Preespective
Metformin A Pharmacological PreespectiveMetformin A Pharmacological Preespective
Metformin A Pharmacological Preespective
 
Antidiabetic drugs
Antidiabetic drugsAntidiabetic drugs
Antidiabetic drugs
 
Pharmacology - Immunosupressants
Pharmacology - ImmunosupressantsPharmacology - Immunosupressants
Pharmacology - Immunosupressants
 
Corticosteroids Pharmacology - drdhriti
Corticosteroids Pharmacology - drdhritiCorticosteroids Pharmacology - drdhriti
Corticosteroids Pharmacology - drdhriti
 
ORAL HYPOGLYCEMIC AGENTS
ORAL HYPOGLYCEMIC AGENTS ORAL HYPOGLYCEMIC AGENTS
ORAL HYPOGLYCEMIC AGENTS
 
Sedatives & hypnotics
Sedatives & hypnoticsSedatives & hypnotics
Sedatives & hypnotics
 
Skeletal muscle relaxant
Skeletal muscle relaxantSkeletal muscle relaxant
Skeletal muscle relaxant
 
Pharmacology of Diuretics
Pharmacology of DiureticsPharmacology of Diuretics
Pharmacology of Diuretics
 
Insulin & Oral Hypoglycemic Agents.
Insulin & Oral Hypoglycemic Agents.Insulin & Oral Hypoglycemic Agents.
Insulin & Oral Hypoglycemic Agents.
 
Antiparkinsonian drugs - drdhriti
Antiparkinsonian drugs - drdhritiAntiparkinsonian drugs - drdhriti
Antiparkinsonian drugs - drdhriti
 
Antidiuretics
AntidiureticsAntidiuretics
Antidiuretics
 

En vedette

Antidiabetic drugs
Antidiabetic drugsAntidiabetic drugs
Antidiabetic drugsDr. Pramod B
 
Diabetic and antidiabetic drugs
Diabetic and antidiabetic drugsDiabetic and antidiabetic drugs
Diabetic and antidiabetic drugsDr_Yousuf
 
Oral hypoglycemics
Oral hypoglycemicsOral hypoglycemics
Oral hypoglycemicsankit
 
Insulin presentation
Insulin presentationInsulin presentation
Insulin presentationAmmar Akhtar
 
Idealp Pharma Hits & Leads Optimisation Case Study 1
Idealp Pharma Hits & Leads Optimisation Case Study 1Idealp Pharma Hits & Leads Optimisation Case Study 1
Idealp Pharma Hits & Leads Optimisation Case Study 1MehdiChelbi
 
Bnf tabulated2
Bnf tabulated2Bnf tabulated2
Bnf tabulated2Emad Hamed
 
In vitro antidiabetic activity
In vitro antidiabetic activityIn vitro antidiabetic activity
In vitro antidiabetic activityRohit K.
 
Pharmacophore modeling: A continuously evolving tool for computational drug d...
Pharmacophore modeling: A continuously evolving tool for computational drug d...Pharmacophore modeling: A continuously evolving tool for computational drug d...
Pharmacophore modeling: A continuously evolving tool for computational drug d...Simone Brogi
 
STARTING INSULIN IN DMII INDIVIDUALIZED APPROACH & INSULINE PREPARATIONS
STARTING INSULIN IN DMII INDIVIDUALIZED APPROACH & INSULINE PREPARATIONSSTARTING INSULIN IN DMII INDIVIDUALIZED APPROACH & INSULINE PREPARATIONS
STARTING INSULIN IN DMII INDIVIDUALIZED APPROACH & INSULINE PREPARATIONSDr. Tariq Elmashharawi
 
230 endocrine system
230 endocrine system230 endocrine system
230 endocrine systemEman Abdallah
 
Anti diabetic drugs
Anti diabetic drugsAnti diabetic drugs
Anti diabetic drugsZam Peace
 
Insulin choices for_diabetics
Insulin choices for_diabeticsInsulin choices for_diabetics
Insulin choices for_diabeticsSUNY Ulster
 
1. Insuline and Anti diabetics
1. Insuline and Anti diabetics1. Insuline and Anti diabetics
1. Insuline and Anti diabeticsMirza Anwar Baig
 

En vedette (20)

Antidiabetic drugs
Antidiabetic drugsAntidiabetic drugs
Antidiabetic drugs
 
Anti diabetics
Anti diabeticsAnti diabetics
Anti diabetics
 
Diabetic and antidiabetic drugs
Diabetic and antidiabetic drugsDiabetic and antidiabetic drugs
Diabetic and antidiabetic drugs
 
Insulin
InsulinInsulin
Insulin
 
Oral hypoglycemics
Oral hypoglycemicsOral hypoglycemics
Oral hypoglycemics
 
Insulin
InsulinInsulin
Insulin
 
Insulin presentation
Insulin presentationInsulin presentation
Insulin presentation
 
Anti tubercular drugs
Anti tubercular drugsAnti tubercular drugs
Anti tubercular drugs
 
Idealp Pharma Hits & Leads Optimisation Case Study 1
Idealp Pharma Hits & Leads Optimisation Case Study 1Idealp Pharma Hits & Leads Optimisation Case Study 1
Idealp Pharma Hits & Leads Optimisation Case Study 1
 
Bnf tabulated2
Bnf tabulated2Bnf tabulated2
Bnf tabulated2
 
project work
project workproject work
project work
 
In vitro antidiabetic activity
In vitro antidiabetic activityIn vitro antidiabetic activity
In vitro antidiabetic activity
 
36.antidiabetic agents
36.antidiabetic agents 36.antidiabetic agents
36.antidiabetic agents
 
Pharmacophore modeling: A continuously evolving tool for computational drug d...
Pharmacophore modeling: A continuously evolving tool for computational drug d...Pharmacophore modeling: A continuously evolving tool for computational drug d...
Pharmacophore modeling: A continuously evolving tool for computational drug d...
 
STARTING INSULIN IN DMII INDIVIDUALIZED APPROACH & INSULINE PREPARATIONS
STARTING INSULIN IN DMII INDIVIDUALIZED APPROACH & INSULINE PREPARATIONSSTARTING INSULIN IN DMII INDIVIDUALIZED APPROACH & INSULINE PREPARATIONS
STARTING INSULIN IN DMII INDIVIDUALIZED APPROACH & INSULINE PREPARATIONS
 
Insulin old & new
Insulin old & newInsulin old & new
Insulin old & new
 
230 endocrine system
230 endocrine system230 endocrine system
230 endocrine system
 
Anti diabetic drugs
Anti diabetic drugsAnti diabetic drugs
Anti diabetic drugs
 
Insulin choices for_diabetics
Insulin choices for_diabeticsInsulin choices for_diabetics
Insulin choices for_diabetics
 
1. Insuline and Anti diabetics
1. Insuline and Anti diabetics1. Insuline and Anti diabetics
1. Insuline and Anti diabetics
 

Similaire à Insulin and antidiabetics

Veterinary Pharmacology of Hormone secreted by pancreas
Veterinary Pharmacology of Hormone secreted by pancreas Veterinary Pharmacology of Hormone secreted by pancreas
Veterinary Pharmacology of Hormone secreted by pancreas Sabal Pokharel
 
Drugs for Diabetes Mellitus
Drugs for Diabetes MellitusDrugs for Diabetes Mellitus
Drugs for Diabetes MellitusArjun Loganathan
 
Kampala international university Glucagon, insulin & oral hypoglycemic drugs.ppt
Kampala international university Glucagon, insulin & oral hypoglycemic drugs.pptKampala international university Glucagon, insulin & oral hypoglycemic drugs.ppt
Kampala international university Glucagon, insulin & oral hypoglycemic drugs.pptYIKIISAAC
 
Anti diabetic agents,Medicinal Chemistry,Mr.Jimmy Alexander ,Associate Profes...
Anti diabetic agents,Medicinal Chemistry,Mr.Jimmy Alexander ,Associate Profes...Anti diabetic agents,Medicinal Chemistry,Mr.Jimmy Alexander ,Associate Profes...
Anti diabetic agents,Medicinal Chemistry,Mr.Jimmy Alexander ,Associate Profes...JIMMYALEX8
 
Anti-diabetic-Agent-SRSharif.pdf
Anti-diabetic-Agent-SRSharif.pdfAnti-diabetic-Agent-SRSharif.pdf
Anti-diabetic-Agent-SRSharif.pdfSakibHasan220057
 
Anti-Diabetic Drugs ppt.pptx
Anti-Diabetic Drugs ppt.pptxAnti-Diabetic Drugs ppt.pptx
Anti-Diabetic Drugs ppt.pptxManu1418
 
Treatment of type ii diabetes by Husna Saqlain
Treatment of type ii diabetes by Husna SaqlainTreatment of type ii diabetes by Husna Saqlain
Treatment of type ii diabetes by Husna SaqlainPARUL UNIVERSITY
 
Anti-Diabetic Drugs ppt.pptx
Anti-Diabetic Drugs ppt.pptxAnti-Diabetic Drugs ppt.pptx
Anti-Diabetic Drugs ppt.pptxManu1418
 
Class oral hypoglycemics
Class oral hypoglycemicsClass oral hypoglycemics
Class oral hypoglycemicsRaghu Prasada
 
Anti-Diabetic Drugs ppt.pptx
Anti-Diabetic Drugs ppt.pptxAnti-Diabetic Drugs ppt.pptx
Anti-Diabetic Drugs ppt.pptxManu1418
 
Antidiabetic drugs-Dr Noopur Verma
Antidiabetic drugs-Dr Noopur VermaAntidiabetic drugs-Dr Noopur Verma
Antidiabetic drugs-Dr Noopur VermaDr Noopur Verma
 
Antidiabetic Drugs
Antidiabetic DrugsAntidiabetic Drugs
Antidiabetic DrugsMrunalAkre
 
Oral hypoglycaemic agents
Oral hypoglycaemic agents   Oral hypoglycaemic agents
Oral hypoglycaemic agents Haider Haider
 

Similaire à Insulin and antidiabetics (20)

Veterinary Pharmacology of Hormone secreted by pancreas
Veterinary Pharmacology of Hormone secreted by pancreas Veterinary Pharmacology of Hormone secreted by pancreas
Veterinary Pharmacology of Hormone secreted by pancreas
 
Hypoglycemic agents
Hypoglycemic agentsHypoglycemic agents
Hypoglycemic agents
 
Diabetes and insulin
Diabetes and insulinDiabetes and insulin
Diabetes and insulin
 
Drugs for Diabetes Mellitus
Drugs for Diabetes MellitusDrugs for Diabetes Mellitus
Drugs for Diabetes Mellitus
 
Kampala international university Glucagon, insulin & oral hypoglycemic drugs.ppt
Kampala international university Glucagon, insulin & oral hypoglycemic drugs.pptKampala international university Glucagon, insulin & oral hypoglycemic drugs.ppt
Kampala international university Glucagon, insulin & oral hypoglycemic drugs.ppt
 
Anti diabetic agents,Medicinal Chemistry,Mr.Jimmy Alexander ,Associate Profes...
Anti diabetic agents,Medicinal Chemistry,Mr.Jimmy Alexander ,Associate Profes...Anti diabetic agents,Medicinal Chemistry,Mr.Jimmy Alexander ,Associate Profes...
Anti diabetic agents,Medicinal Chemistry,Mr.Jimmy Alexander ,Associate Profes...
 
Anti-diabetic-Agent-SRSharif.pdf
Anti-diabetic-Agent-SRSharif.pdfAnti-diabetic-Agent-SRSharif.pdf
Anti-diabetic-Agent-SRSharif.pdf
 
Diabetes treatment
Diabetes treatmentDiabetes treatment
Diabetes treatment
 
Anti-Diabetic Drugs ppt.pptx
Anti-Diabetic Drugs ppt.pptxAnti-Diabetic Drugs ppt.pptx
Anti-Diabetic Drugs ppt.pptx
 
Treatment of type ii diabetes by Husna Saqlain
Treatment of type ii diabetes by Husna SaqlainTreatment of type ii diabetes by Husna Saqlain
Treatment of type ii diabetes by Husna Saqlain
 
Anti-Diabetic Drugs ppt.pptx
Anti-Diabetic Drugs ppt.pptxAnti-Diabetic Drugs ppt.pptx
Anti-Diabetic Drugs ppt.pptx
 
Insulin
InsulinInsulin
Insulin
 
Class oral hypoglycemics
Class oral hypoglycemicsClass oral hypoglycemics
Class oral hypoglycemics
 
Anti-Diabetic Drugs ppt.pptx
Anti-Diabetic Drugs ppt.pptxAnti-Diabetic Drugs ppt.pptx
Anti-Diabetic Drugs ppt.pptx
 
Antidiabetic drugs-Dr Noopur Verma
Antidiabetic drugs-Dr Noopur VermaAntidiabetic drugs-Dr Noopur Verma
Antidiabetic drugs-Dr Noopur Verma
 
Antidiabetic Drugs
Antidiabetic DrugsAntidiabetic Drugs
Antidiabetic Drugs
 
Insulin 2020
Insulin 2020Insulin 2020
Insulin 2020
 
Oral hypoglycaemic agents
Oral hypoglycaemic agents   Oral hypoglycaemic agents
Oral hypoglycaemic agents
 
Diabetes Mellitus
Diabetes MellitusDiabetes Mellitus
Diabetes Mellitus
 
Insulin
InsulinInsulin
Insulin
 

Plus de DrVishal Kandhway

Plus de DrVishal Kandhway (7)

Brain death
Brain deathBrain death
Brain death
 
TURP
TURPTURP
TURP
 
Neuromuscular physiology
Neuromuscular physiologyNeuromuscular physiology
Neuromuscular physiology
 
Effects of anesthesia on mother and baby
Effects of anesthesia on mother and babyEffects of anesthesia on mother and baby
Effects of anesthesia on mother and baby
 
Iv cannula technique
Iv cannula techniqueIv cannula technique
Iv cannula technique
 
Ketamine
KetamineKetamine
Ketamine
 
Anticholinergic drugs
Anticholinergic drugsAnticholinergic drugs
Anticholinergic drugs
 

Dernier

FDMA FLAP - The first dorsal metacarpal artery (FDMA) flap is used mainly for...
FDMA FLAP - The first dorsal metacarpal artery (FDMA) flap is used mainly for...FDMA FLAP - The first dorsal metacarpal artery (FDMA) flap is used mainly for...
FDMA FLAP - The first dorsal metacarpal artery (FDMA) flap is used mainly for...Shubhanshu Gaurav
 
Clinical Research Informatics Year-in-Review 2024
Clinical Research Informatics Year-in-Review 2024Clinical Research Informatics Year-in-Review 2024
Clinical Research Informatics Year-in-Review 2024Peter Embi
 
pA2 value, Schild plot and pD2 values- applications in pharmacology
pA2 value, Schild plot and pD2 values- applications in pharmacologypA2 value, Schild plot and pD2 values- applications in pharmacology
pA2 value, Schild plot and pD2 values- applications in pharmacologyDeepakDaniel9
 
Red Blood Cells_anemia & polycythemia.pdf
Red Blood Cells_anemia & polycythemia.pdfRed Blood Cells_anemia & polycythemia.pdf
Red Blood Cells_anemia & polycythemia.pdfMedicoseAcademics
 
Adenomyosis or Fibroid- making right diagnosis
Adenomyosis or Fibroid- making right diagnosisAdenomyosis or Fibroid- making right diagnosis
Adenomyosis or Fibroid- making right diagnosisSujoy Dasgupta
 
High-Performance Thin-Layer Chromatography (HPTLC)
High-Performance Thin-Layer Chromatography (HPTLC)High-Performance Thin-Layer Chromatography (HPTLC)
High-Performance Thin-Layer Chromatography (HPTLC)kishan singh tomar
 
CONNECTIVE TISSUE (ANATOMY AND PHYSIOLOGY).pdf
CONNECTIVE TISSUE (ANATOMY AND PHYSIOLOGY).pdfCONNECTIVE TISSUE (ANATOMY AND PHYSIOLOGY).pdf
CONNECTIVE TISSUE (ANATOMY AND PHYSIOLOGY).pdfDolisha Warbi
 
Mental health Team. Dr Senthil Thirusangu
Mental health Team. Dr Senthil ThirusanguMental health Team. Dr Senthil Thirusangu
Mental health Team. Dr Senthil Thirusangu Medical University
 
power point presentation of Clinical evaluation of strabismus
power point presentation of Clinical evaluation  of strabismuspower point presentation of Clinical evaluation  of strabismus
power point presentation of Clinical evaluation of strabismusChandrasekar Reddy
 
SGK RỐI LOẠN KALI MÁU CỰC KỲ QUAN TRỌNG.pdf
SGK RỐI LOẠN KALI MÁU CỰC KỲ QUAN TRỌNG.pdfSGK RỐI LOẠN KALI MÁU CỰC KỲ QUAN TRỌNG.pdf
SGK RỐI LOẠN KALI MÁU CỰC KỲ QUAN TRỌNG.pdfHongBiThi1
 
blood bank management system project report
blood bank management system project reportblood bank management system project report
blood bank management system project reportNARMADAPETROLEUMGAS
 
PAIN/CLASSIFICATION AND MANAGEMENT OF PAIN.pdf
PAIN/CLASSIFICATION AND MANAGEMENT OF PAIN.pdfPAIN/CLASSIFICATION AND MANAGEMENT OF PAIN.pdf
PAIN/CLASSIFICATION AND MANAGEMENT OF PAIN.pdfDolisha Warbi
 
Bulimia nervosa ( Eating Disorders) Mental Health Nursing.
Bulimia nervosa ( Eating Disorders) Mental Health Nursing.Bulimia nervosa ( Eating Disorders) Mental Health Nursing.
Bulimia nervosa ( Eating Disorders) Mental Health Nursing.aarjukhadka22
 
MedMatch: Your Health, Our Mission. Pitch deck.
MedMatch: Your Health, Our Mission. Pitch deck.MedMatch: Your Health, Our Mission. Pitch deck.
MedMatch: Your Health, Our Mission. Pitch deck.whalesdesign
 
SGK LEUKEMIA KINH DÒNG BẠCH CÂU HẠT HAY.pdf
SGK LEUKEMIA KINH DÒNG BẠCH CÂU HẠT HAY.pdfSGK LEUKEMIA KINH DÒNG BẠCH CÂU HẠT HAY.pdf
SGK LEUKEMIA KINH DÒNG BẠCH CÂU HẠT HAY.pdfHongBiThi1
 
BENIGN BREAST DISEASE
BENIGN BREAST DISEASE BENIGN BREAST DISEASE
BENIGN BREAST DISEASE Mamatha Lakka
 

Dernier (20)

FDMA FLAP - The first dorsal metacarpal artery (FDMA) flap is used mainly for...
FDMA FLAP - The first dorsal metacarpal artery (FDMA) flap is used mainly for...FDMA FLAP - The first dorsal metacarpal artery (FDMA) flap is used mainly for...
FDMA FLAP - The first dorsal metacarpal artery (FDMA) flap is used mainly for...
 
Clinical Research Informatics Year-in-Review 2024
Clinical Research Informatics Year-in-Review 2024Clinical Research Informatics Year-in-Review 2024
Clinical Research Informatics Year-in-Review 2024
 
pA2 value, Schild plot and pD2 values- applications in pharmacology
pA2 value, Schild plot and pD2 values- applications in pharmacologypA2 value, Schild plot and pD2 values- applications in pharmacology
pA2 value, Schild plot and pD2 values- applications in pharmacology
 
Rheumatoid arthritis Part 1, case based approach with application of the late...
Rheumatoid arthritis Part 1, case based approach with application of the late...Rheumatoid arthritis Part 1, case based approach with application of the late...
Rheumatoid arthritis Part 1, case based approach with application of the late...
 
Red Blood Cells_anemia & polycythemia.pdf
Red Blood Cells_anemia & polycythemia.pdfRed Blood Cells_anemia & polycythemia.pdf
Red Blood Cells_anemia & polycythemia.pdf
 
Adenomyosis or Fibroid- making right diagnosis
Adenomyosis or Fibroid- making right diagnosisAdenomyosis or Fibroid- making right diagnosis
Adenomyosis or Fibroid- making right diagnosis
 
Immune labs basics part 1 acute phase reactants ESR, CRP Ahmed Yehia Ismaeel,...
Immune labs basics part 1 acute phase reactants ESR, CRP Ahmed Yehia Ismaeel,...Immune labs basics part 1 acute phase reactants ESR, CRP Ahmed Yehia Ismaeel,...
Immune labs basics part 1 acute phase reactants ESR, CRP Ahmed Yehia Ismaeel,...
 
High-Performance Thin-Layer Chromatography (HPTLC)
High-Performance Thin-Layer Chromatography (HPTLC)High-Performance Thin-Layer Chromatography (HPTLC)
High-Performance Thin-Layer Chromatography (HPTLC)
 
CONNECTIVE TISSUE (ANATOMY AND PHYSIOLOGY).pdf
CONNECTIVE TISSUE (ANATOMY AND PHYSIOLOGY).pdfCONNECTIVE TISSUE (ANATOMY AND PHYSIOLOGY).pdf
CONNECTIVE TISSUE (ANATOMY AND PHYSIOLOGY).pdf
 
How to master Steroid (glucocorticoids) prescription, different scenarios, ca...
How to master Steroid (glucocorticoids) prescription, different scenarios, ca...How to master Steroid (glucocorticoids) prescription, different scenarios, ca...
How to master Steroid (glucocorticoids) prescription, different scenarios, ca...
 
Mental health Team. Dr Senthil Thirusangu
Mental health Team. Dr Senthil ThirusanguMental health Team. Dr Senthil Thirusangu
Mental health Team. Dr Senthil Thirusangu
 
power point presentation of Clinical evaluation of strabismus
power point presentation of Clinical evaluation  of strabismuspower point presentation of Clinical evaluation  of strabismus
power point presentation of Clinical evaluation of strabismus
 
SGK RỐI LOẠN KALI MÁU CỰC KỲ QUAN TRỌNG.pdf
SGK RỐI LOẠN KALI MÁU CỰC KỲ QUAN TRỌNG.pdfSGK RỐI LOẠN KALI MÁU CỰC KỲ QUAN TRỌNG.pdf
SGK RỐI LOẠN KALI MÁU CỰC KỲ QUAN TRỌNG.pdf
 
GOUT UPDATE AHMED YEHIA 2024, case based approach with application of the lat...
GOUT UPDATE AHMED YEHIA 2024, case based approach with application of the lat...GOUT UPDATE AHMED YEHIA 2024, case based approach with application of the lat...
GOUT UPDATE AHMED YEHIA 2024, case based approach with application of the lat...
 
blood bank management system project report
blood bank management system project reportblood bank management system project report
blood bank management system project report
 
PAIN/CLASSIFICATION AND MANAGEMENT OF PAIN.pdf
PAIN/CLASSIFICATION AND MANAGEMENT OF PAIN.pdfPAIN/CLASSIFICATION AND MANAGEMENT OF PAIN.pdf
PAIN/CLASSIFICATION AND MANAGEMENT OF PAIN.pdf
 
Bulimia nervosa ( Eating Disorders) Mental Health Nursing.
Bulimia nervosa ( Eating Disorders) Mental Health Nursing.Bulimia nervosa ( Eating Disorders) Mental Health Nursing.
Bulimia nervosa ( Eating Disorders) Mental Health Nursing.
 
MedMatch: Your Health, Our Mission. Pitch deck.
MedMatch: Your Health, Our Mission. Pitch deck.MedMatch: Your Health, Our Mission. Pitch deck.
MedMatch: Your Health, Our Mission. Pitch deck.
 
SGK LEUKEMIA KINH DÒNG BẠCH CÂU HẠT HAY.pdf
SGK LEUKEMIA KINH DÒNG BẠCH CÂU HẠT HAY.pdfSGK LEUKEMIA KINH DÒNG BẠCH CÂU HẠT HAY.pdf
SGK LEUKEMIA KINH DÒNG BẠCH CÂU HẠT HAY.pdf
 
BENIGN BREAST DISEASE
BENIGN BREAST DISEASE BENIGN BREAST DISEASE
BENIGN BREAST DISEASE
 

Insulin and antidiabetics

  • 1. INSULIN AND ANTIDIABETIC DRUGS BY DR VISHAL KR KANDHWAY JNMC, SAWANGI (MEGHE), WARDHA
  • 2. PANCREATIC AXIS INSULIN -β cells secrete due to high blood glucose levels -Glucose uptake into tissues increases GLUCAGON -α cells secrete when blood glucose is low -Glucose is released from tissues back into blood
  • 3. GLUCOSE HOMEOSTASIS Body Cells take up more glucose Liver takes up glucose and stores it as glycogen Blood glucose level declines to a set point; stimulus for insulin release diminishes Homeostasis: Normal blood glucose level (about 90 mg/100 mL) STIMULUS: Rising blood glucose level (e.g., after eating a carbohydrate-rich meal) Beta cells of pancreas stimulated to release insulin into the blood High blood glucose level Blood glucose level rises to set point; stimulus for glucagon release diminishes Liver breaks down glycogen and releases glucose to the blood Glucagon Alpha cells of pancreas stimulated to release glucagon into the blood STIMULUS: Declining blood glucose level (e.g., after skipping a meal) Insulin
  • 4. NORMAL GLUCOSE CONTROL  Post-absorptive period - normal individual-low basal levels of circulating insulin maintained through constant β cell secretion- suppression of lipolysis, proteolysis and glycogenolysis.  After ingesting a meal-burst of insulin secretion in response to elevated glucose and amino acid levels.  When glucose levels return to basal levels- insulin secretion returns to its basal level.
  • 5. DIABETES MELLITUS -Definition- Diabetes is a heterogeneous group of syndromes characterized by the elevation of glucose levels due to a relative or absolute deficiency of insulin. -It is characterized by- 1. High level of glucose in urine and fasting blood 2. Polyuria 3. Polydypsia 4. Fatigue 5. Constant hunger
  • 6. TYPES  Type 1 DM: - “Childhood” diabetes (sudden onset, before age 15) - Lack of functional pancreatic β-cells (T cell-mediated autoimmune response destroys beta cells) - Lack of functional β-cells prevents mitigation of elevated glucose levels and associated insulin responses. - Controlled by insulin injections.  Type 2 DM: - “Adult” diabetes (after age 40, obese individuals) - Insulin levels are normal or elevated but there is either a decrease in number of insulin receptors or the cells cannot take it up. - Actual insulin levels may be normal or supra-normal but it is ineffective (insulin resistance). - Controlled by dietary changes and regular exercise.
  • 7. TREATMENT  Type I DM : - Depend on exogenous insulin to prevent hyperglycemia and avoid ketoacidosis. - The goal of therapy is to mimic both the basal and reactive secretion of insulin in response to glucose levels avoiding both hyper- and hypo-glycemic episodes.  Type II DM: - The goal of treatment is to maintain glucose concentrations within normal limits to prevent long term complications. - Weight reduction, exercise and dietary modification decrease insulin resistance - essential steps in the treatment regimen. - Addition of hypoglycemic agents is often required, often insulin therapy is also required.
  • 8. INSULIN  Insulin- peptide hormone synthesized in the beta cells of islets of Langerhans in the Pancreas.  Produced as a polypeptide- Pro insulin (precursor)  Proinsulin converted to insulin and C-peptide and stored in the secretory granules.  Stimulation leads to release of secretory granules.
  • 9. MECHANISM OF ACTION  Secretion elicited by elevated glucose levels  Increased glucose levels in β-cells results in increased ATP levels, this results in a block of K+ channels causing membrane depolarization which opens Ca2+ channels.  The influx of Ca2+ results in a pulsatile secretion of insulin.  Many insulin stimulated cascades are activated mainly translocation of GLUT 4 glucose transporters to plasma membranes causing- 1. Glucose diffusion into cells 2. Activates glycogen synthetase and thus glucose stored as glycogen 3. Stimulate uptake of amino acids, potassium and magnesium 4. Stimulate protein synthesis and inhibit proteolysis  1 unit of can account for 30 grams of carbohydrate  1 unit can lower 50 mg/dL blood glucose
  • 10. ACTION OF INSULIN ON VARIOUS TISSUES LIVER MUSCLE ADIPOSE ↓ GLUCOSE PRODUCTION ↑ GLUCOSE TRANSPORT ↑ GLUCOSE TRANSPORT ↑ GLYCOLYSIS ↑ GLYCOLYSIS ↑ LIPOGENESIS& LIPOPROTEIN LIPASE ACTIVITY ↑ TG SYNTHESIS ↑ GLYCOGEN DEPOSITION ↓ INTRACELLULAR LIPOLYSIS ↑ PROTEIN SYNTHESIS ↑ PROTEIN SYNTHESIS
  • 11. The Synthesis and Release of Insulin is modulated by: 1. Glucose (most important) and ketone bodies stimulate release. 2. Glucagon and somatostation inhibit release 3. α-Adrenergic stimulation inhibits release (most important). 4. β-Adrenergic stimulation promotes release. 5. Elevated intracellular Ca2+ promotes release.
  • 12. PHARMACOKINETICS  Elimination t ½ of IV insulin- 5 to 10 minutes  Metabolized by kidneys and liver  Insulin tightly bound to tissue receptors- so even though rapid clearance, pharmacologic effects remain till 30-60 minutes.  Insulin secreted into portal venous system at rate of 1 unit/hour  Daily secretion of insulin is 40 units.  Insulin response to glucose is greater for oral ingestion than for iv infusion.
  • 13. PREPARATIONS HOURS AFTER SUBCUTANEOUS ADMINISTRATION INSULIN PREPARATION ONSET PEAK DURATION RAPID ACTING REGULAR CRYSTALLINE ZINC 0.5-1.0 2-3 6-8 VERY RAPID ACTING LISPRO ASPART 0.25-0.5 0.5-1.5 4-6 INTERMEDIATE ACTING LENTE(NPH) 1 4-8 10-14 LONG ACTING ULTRALENTE GLARGINE 1 1.5 10-14 none 18-24 30
  • 14. THE GOAL OF INSULIN THERAPY
  • 15. PREPARATIONS  Regular Insulin - Fast acting (rapid acting) - Only type which can be given IV as well as SC - Six molecules linked with a zinc molecule to form hexamer - For abrupt onset hyperglycemia or ketoacidosis - Single iv injection 1-5Units/ continuous infusion of 0.5-2 units/hour
  • 16.  VERY RAPID ACTING- LISPRO/ INSULIN ASPART/ GLULISINE- (ultrashort acting) - More rapid than regular insulin and shorter duration - Less Associated hypoglycemia but recurrent hyperglycemia before next meal due to shorter duration of action. - Given just 15 minutes prior to meals - Provides a postprandial plasma insulin concentration like normal insulin.  INTERMEDIATE ACTING- LENTE (NPH) - Absorption delayed due to conjugation with protamine(0.005mg/unit)  LONG ACTING- ULTRALENTE, GLARGINE - Given as single bedtime injection - Lesser nocturnal hypoglycemia
  • 18. ADVERSE EFFECTS OF INSULIN  Hypoglycemia  Allergic reactions  Lipodystrophy  Insulin resistance  Hypokalemia  Weight gain
  • 19. ORAL HYPOGLYCEMICS  These agents are useful in the treatment of Type 2 DM who do not respond adequately to non-medical interventions (diet, exercise and weight loss).  Newly diagnosed Type 2 DM (less than 5 years) often respond well to oral agents  Patients with long standing disease (often diagnosed late) require a combination of agents with or without insulin.  The progressive decline in β-cell function often necessitates the addition of insulin at some time in Type II DM. Oral agents are never indicated for Type I DM.
  • 20. SULFONYLUREAS  Promote the release of insulin from β-cells (secretogogues)  Mechanism of action:  These agents require functioning β-cells, they stimulate release by blocking ATP-sensitive K+ channels resulting in depolarization with Ca2+ influx which promotes insulin secretion.  They also reduce glucagon secretion and increase the binding of insulin to target tissues.  They may also increase the number of insulin receptors -Adverse Effects: Weight gain, Hyperinsulinemia and Hypoglycemia. Hepatic or renal insufficiency causes accumulation of these agents promoting the risk of hypoglycemia.  Tolbutamide is asociated with a 2.5 times rise in cardiovascular mortality.
  • 21. Onset and Duration  Short acting: Tolbutamide  Intermediate acting: Glipizide ,Glyburide  Long acting: Chloropropamide, Glimepride
  • 22. MEGLITINIDES  Agents -Repaglinide and Nateglinide act as Secretogogues.  Prompt peak effect (1 hour) and shorter duration of action (about 4 hours)  Taken 15-30 mins before meals  Decreases risk of prolonged hypoglycemia due to short duration of action.  When used in combination with other oral agents they produce better control than any monotherapy.
  • 23. BIGUANIDES  METFORMIN - Classified as an insulin sensitizer- increases glucose uptake and utilization by target tissues - Mechanism of action : Reduces plasma glucose levels by inhibiting hepatic gluconeogenesis. - It also reduces hyperlipidemia (↓LDL and VLDL cholesterol and ↑ HDL). Lipid lowering requires 4-6 weeks of treatment. - Metformin also decreases appetite. - It is the only oral hypoglycemic shown to reduce cardiovascular mortality. - Adverse effects: Hypoglycemia occurs only when combined with other agents. Rarely severe lactic acidosis is associated with metformin use particularly in diabetics with CHF. Drug interactions with cimetidine, furosemide, nifedipine and others have been identified.
  • 24. THIAZOLIDINEDIONES (GLITAZONES)  PIOGLITAZONE and ROSIGLITAZONE  These agents are insulin sensitizers  They do not promote insulin secretion from β-cells but insulin is necessary for them to be effective  Act principally at adipose tissue and skeletal muscles to decrease insulin resistance  Clinical effect takes 4-12 weeks to be evident  SIDE EFFECTS- Weight gain, can induce hepatic dysfunction
  • 25. ΑLPHA-GLUCOSIDASE INHIBITORS  Acarbose and miglitol are two agents of this class used for type 2 diabetes Mechanism of action: These agents are oligosaccharide derivatives taken at the beginning of a meal ; delay carbohydrate digestion by competitively inhibiting α-glucosidase, a membrane bound enzyme of the intestinal brush border. Adverse Effects: Flatulence, diarrhea, cramping. Metformin bioavailability is severely decreased when used concomitantly. These agents should not be used in diabetics with intestinal pathology.
  • 27. REFERENCES  Stoelting’s pharmacology and physiology in anaesthetic practice